Page last updated: 2024-12-07

fumitremorgin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

fumitremorgin B: intermediary in TR-2 mycotoxin biosyn; RN given refers to (5aR-(5aalpha,6alpha,12beta,14aalpha))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fumitremorgin B : An organic heteropentacyclic compound that is a mycotoxic indole alkaloid produced by several fungi via a tryptophan-proline diketopiperazine intermediate. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID105113
CHEMBL ID3885413
CHEBI ID64531
SCHEMBL ID3127635
MeSH IDM0117711

Synonyms (23)

Synonym
5h,14h-pyrrolo(1'',2'':4',5')pyrazino(1',2':1,6)pyrido(3,4-b)indole-5,14-dione, 1,2,3,5a,6,11,12,14a-octahydro-5a,6-dihydroxy-9-methoxy-11-(3-methyl-2-butenyl)-12-(2-methyl-1-propenyl)-, (5ar-(5a-alpha,6-alpha,12-beta,14a-alpha))-
lanosulin
fumitremorgin b
5h,14h-pyrrolo(1'',2'':4',5')pyrazino(1',2':1,6)pyrido(3,4-b)indole-5,14-dione, 1,2,3,5a,6,11,12,14a-octahydro-5a,6-dihydroxy-9-methoxy-11-(3-methyl-2-butenyl)-12-(2-methyl-1-propenyl)-, (5ar,6s,12s,14as)-
12626-17-4
(5ar,6s,12s,14as)-5a,6-dihydroxy-9-methoxy-11-(3-methylbut-2-en-1-yl)-12-(2-methylprop-1-en-1-yl)-1,2,3,5a,6,11,12,14a-octahydro-5h,14h-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,14-dione
itn5b384f8 ,
unii-itn5b384f8
CHEBI:64531
C20630
5h,14h-pyrrolo(1'',2'':4',5')pyrazino(1',2':1,6)pyrido(3,4-b)indole-5,14-dione, 1,2,3,5a,6,11,12,14a-octahydro-5a,6-dihydroxy-9-methoxy-11-(3-methyl-2-buten-1-yl)-12-(2-methyl-1-propen-1-yl)-, (5ar,6s,12s,14as)-
na-209b
SCHEMBL3127635
fumitremorgen b
1,2-dihydroxy-7-methoxy-10-(3-methylbut-2-enyl)-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
CHEMBL3885413
4Q1 ,
DTXSID70925478
Q27133338
(1r,2s,12s,15s)-1,2-dihydroxy-7-methoxy-10-(3-methylbut-2-enyl)-12-(2-methylprop-1-enyl)-10,13,19-triazapentacyclo[11.7.0.03,11.04,9.015,19]icosa-3(11),4(9),5,7-tetraene-14,20-dione
HY-117313
CS-0065271
AKOS040761753

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Verrucosidin appeared to have the highest toxic potential, testing positive in both assays."( Genotoxicity assessment of five tremorgenic mycotoxins (fumitremorgen B, paxilline, penitrem A, verruculogen, and verrucosidin) produced by molds isolated from fermented meats.
Fink-Gremmels, J; Nijmeijer, S; Sabater-Vilar, M, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
mycotoxinPoisonous substance produced by fungi.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic heteropentacyclic compound
indole alkaloidAn alkaloid containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
fumitremorgin A biosynthesis412
superpathway of fumitremorgin biosynthesis925

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1336110Inhibition of BCRP in human K562 cells assessed as potentiation of SN38-mediated growth inhibition at 3 uM after 4 days by coulter counter method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336104Cytotoxicity against human HeLa cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336106Cytotoxicity against human HT-29 cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336103Cytotoxicity against human Jurkat cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336105Cytotoxicity against human MCF7 cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336111Inhibition of BCRP (unknown origin)-dependent ATPase activity at 50 uM after 30 mins by malachite green method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's4 (25.00)18.2507
2000's3 (18.75)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.54 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]